pANCA and ASCA in Children with IBD-Unclassified, Crohn's Colitis, and Ulcerative Colitis—A Longitudinal Report from the IBD Porto Group of ESPGHAN

Introduction:No study to date has evaluated perinuclear antineutrophil cytoplasmic antibody (pANCA) and anti–Saccharomyces cerevisiae antibody (ASCA) in pediatric inflammatory bowel disease–unclassified (IBDU) as compared with Crohn's colitis (CC) and ulcerative colitis (UC), which represent the diagnostic challenge. We aimed to explore the diagnostic utility of serology and to assess whether serology can predict disease severity in these subgroups. Methods:This was a multicenter retrospective longitudinal study including 406 children with inflammatory bowel diseases (IBD) from 23 centers affiliated with the Porto group of European Society of Pediatric Gastroenterology, Hepatology and Nutrition (mean age 10.5 ± 3.9, 54% males); 117 (29%) with CC, 143 (35%) with UC, and 146 (36%) with IBDU. Median follow-up period was 2.8 years (interquartile range, 1.6–4.2). Results:The most prevalent serologic profile in IBDU was pANCA−/ASCA− (41%), followed by pANCA+/ASCA− (34%) and pANCA−/ASCA+ (17%). pANCA−/ASCA+ differentiated well between CC versus IBDU (83% specificity, 96% positive predictive value [PPV]) and UC (97% specificity, 90% PPV) patients, albeit with a low negative predictive value (13% and 40%, respectively). pANCA+/ASCA− did not differentiate as well between IBD subgroups, but UC children with pANCA+/ASCA− had more often severe disease at diagnosis (36 [62%] versus 22 [38%], P = 0.033) and needed more often calcineurin inhibitors, biologics, or colectomy (25 [80%] versus 6 [20%], P = 0.026). In CC, double positivity for ASCA and not pANCA−/ASCA+ profile was associated with disease severity. Conclusions:Serology may have some role in predicting disease course and outcomes in colonic IBD, but its routine use needs to be supported by more studies. Serology cannot routinely be recommended for differentiating between IBDU versus CC or UC as a sole diagnostic criterion given its low diagnostic utility.

[1]  Helmut Neumann,et al.  Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives. , 2015, World journal of gastroenterology.

[2]  G. Veres,et al.  ESPGHAN Revised Porto Criteria for the Diagnosis of Inflammatory Bowel Disease in Children and Adolescents , 2013, Journal of pediatric gastroenterology and nutrition.

[3]  E. Nimmo,et al.  Beyond Gene Discovery in Inflammatory Bowel Disease: The Emerging Role of Epigenetics , 2013, Gastroenterology.

[4]  M. Kekıllı,et al.  Atypical pANCA as a marker of indeterminate colitis for the prediction of ulcerative colitis and crohn’s disease
 , 2013, Wiener klinische Wochenschrift.

[5]  A. Kuna Serological markers of inflammatory bowel disease , 2013, Biochemia medica.

[6]  S. Ng,et al.  Serological Antibodies in Inflammatory Bowel Disease: A Systematic Review , 2012, Inflammatory bowel diseases.

[7]  F. Klebl,et al.  Clinical Utility of Anti‐Glycan Antibodies in Pediatric Crohn's Disease in Comparison with An Adult Cohort , 2012, Inflammatory bowel diseases.

[8]  David C Wilson,et al.  Pediatric modification of the Montreal classification for inflammatory bowel disease: The Paris classification , 2011, Inflammatory bowel diseases.

[9]  Judy H. Cho,et al.  Recent insights into the genetics of inflammatory bowel disease. , 2011, Gastroenterology.

[10]  J. Lewis The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. , 2011, Gastroenterology.

[11]  Simon C. Potter,et al.  Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region , 2009, Nature Genetics.

[12]  S. Brand Crohn’s disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn’s disease , 2009, Gut.

[13]  M. Vatn,et al.  Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study) , 2009, Scandinavian journal of gastroenterology.

[14]  S. Targan,et al.  Increased immune reactivity predicts aggressive complicating Crohn's disease in children. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[15]  M. Vatn,et al.  Serological markers are associated with disease course in ulcerative colitis. A study in an unselected population-based cohort followed for 10 years. , 2008, Journal of Crohn's & colitis.

[16]  T. Molnár,et al.  New Serological Markers for Inflammatory Bowel Disease Are Associated With Earlier Age at Onset, Complicated Disease Behavior, Risk for Surgery, and NOD2/CARD15 Genotype in a Hungarian IBD Cohort , 2008, The American Journal of Gastroenterology.

[17]  K. Van Steen,et al.  New serological markers in inflammatory bowel disease are associated with complicated disease behaviour , 2007, Gut.

[18]  A. Darzi,et al.  Diagnostic Precision of Anti-Saccharomyces cerevisiae Antibodies and Perinuclear Antineutrophil Cytoplasmic Antibodies in Inflammatory Bowel Disease , 2006, The American Journal of Gastroenterology.

[19]  Richard E Thompson,et al.  Indeterminate colitis: A significant subgroup of pediatric IBD , 2006, Inflammatory bowel diseases.

[20]  Dennis Christie,et al.  Serum Immune Responses Predict Rapid Disease Progression among Children with Crohn's Disease: Immune Responses Predict Disease Progression , 2006, The American Journal of Gastroenterology.

[21]  B. Sands,et al.  A male with a pelvic mass , 2004, Gut.

[22]  S. Plevy Do Serological Markers and Cytokines Determine the Indeterminate? , 2004, Journal of clinical gastroenterology.

[23]  M. Dubinsky,et al.  Utility of serum antibodies in determining clinical course in pediatric Crohn's disease. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[24]  P. Rutgeerts,et al.  The value of serologic markers in indeterminate colitis: a prospective follow-up study. , 2003, Gastroenterology.

[25]  P. Rutgeerts,et al.  Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease , 2001, American Journal of Gastroenterology.

[26]  S. Targan,et al.  Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role , 1998, Gut.

[27]  S. Targan,et al.  Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. , 1996, Gastroenterology.

[28]  S. Targan,et al.  Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. , 1996, Mayo Clinic proceedings.

[29]  S. Hanauer,et al.  Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. , 1993, The American journal of gastroenterology.

[30]  G. Lichtenstein New serological markers in inflammatory bowel disease are associated with complicated disease behaviour , 2008 .

[31]  Y. Yoshida,et al.  [Indeterminate colitis]. , 1994, Ryoikibetsu shokogun shirizu.

[32]  E. J. Smith A children's hospital in a medical center , 1947 .